Adagene Inc.
corporate_fare Company Profile
Adagene Inc. (NASDAQ:ADAG) is a publicly traded company in the Life Sciences sector. Wiseek monitors ADAG SEC EDGAR filings and licensed market news in real time, scoring each submission for market-moving significance on a 1–10 scale. Items rated 7 or higher generate instant alerts.
Recent high-impact activity:
- CEO Peter Luo no longer attributed beneficial ownership of 11.20% stake held by family trust
- Adagene's Muzastotug Shows Strong Efficacy and Favorable Safety in Combination Therapies for HCC and MSS CRC
- Adagene Finalizes $70M Public Offering at Discount to Fund R&D After Positive Clinical Data
- Adagene Prices $70M Public Offering, Securing Capital for Pipeline
- Adagene Files Preliminary Prospectus for ADS Offering Amidst Strong Clinical Data & FDA Fast Track Designation
Financial Snapshot
Dilution Risk
Low riskFiling-implied dilution signals for ADAG, detected from its recent SEC filings · latest filing 2026-04-02.
Public Offering Priced · Significant Dilution
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →
Insider Transactions
ADAG files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.